160 related articles for article (PubMed ID: 8732094)
41. Apoptotic and proliferative activity in ovarian benign, borderline and malignant tumors.
Liu A; Chen L; Ngan HY; Khoo US; Zhao Y; Cheung AN
Chin Med Sci J; 2002 Jun; 17(2):106-11. PubMed ID: 12906164
[TBL] [Abstract][Full Text] [Related]
42. Expression of heparanase, Mdm2, and erbB2 in ovarian cancer.
Ginath S; Menczer J; Friedmann Y; Aingorn H; Aviv A; Tajima K; Dantes A; Glezerman M; Vlodavsky I; Amsterdam A
Int J Oncol; 2001 Jun; 18(6):1133-44. PubMed ID: 11351242
[TBL] [Abstract][Full Text] [Related]
43. A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors.
Němejcová K; Bártů MK; Michálková R; Drozenová J; Fabian P; Fadare O; Hausnerová J; Laco J; Matěj R; Méhes G; Singh N; Stolnicu S; Škapa P; Švajdler M; Stružinská I; Cibula D; Kocian R; Lax SF; McCluggage WG; Dundr P
Diagn Pathol; 2023 Feb; 18(1):15. PubMed ID: 36740684
[TBL] [Abstract][Full Text] [Related]
44. [Prostatic adenocarcinoma showing features of endometrioid and mucinous carcinomas: a case report].
Nishimura K; Higashino M; Hara T; Oka T
Hinyokika Kiyo; 1995 Oct; 41(10):805-7. PubMed ID: 8533679
[TBL] [Abstract][Full Text] [Related]
45. [The relationship between carcinoembryonic antigen (CEA) expression and histogenesis of gastric cancer (application of immunohistochemical and mucin histochemical techniques)].
Wu JF
Zhonghua Zhong Liu Za Zhi; 1992 Jan; 14(1):13-6. PubMed ID: 1327687
[TBL] [Abstract][Full Text] [Related]
46. Comparative measurement of ovarian carcinoma antigen and carcinoembryonic antigen in the serum of ovarian cancer.
Yuan CC; Ng HT; Tsai LC; Jeng FS; Yeh SH; Tsai YC
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1987 Aug; 20(3):190-7. PubMed ID: 3480793
[TBL] [Abstract][Full Text] [Related]
47. Aberrant expression of intestinal mucin antigens associated with colorectal carcinoma defined by a panel of monoclonal antibodies.
Hertzog PJ; Pilbrow SJ; Pedersen J; Polglase AL; Lawson M; Linnane AW
Br J Cancer; 1991 Nov; 64(5):799-808. PubMed ID: 1931599
[TBL] [Abstract][Full Text] [Related]
48. Carcinoembryonic antigen isotypes in tissue sections and loose cyst fluid cells of ovarian neoplasms.
Harłozińska A; Bar JK; Jothy S; Sedlaczek P; Slesak B; Richter R
Tumour Biol; 1993; 14(1):1-8. PubMed ID: 7684152
[TBL] [Abstract][Full Text] [Related]
49. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
50. Ovarian tumors of low malignant potential (borderline tumors): immune morphology and current status.
Neunteufel W; Gitsch G; Schieder K; Kölbl H; Breitenecker G
Anticancer Res; 1989; 9(4):993-7. PubMed ID: 2684001
[TBL] [Abstract][Full Text] [Related]
51. Emergence of CA125 immunoreactivity in recurrent or metastatic primary ovarian mucinous neoplasms of the intestinal type.
Miller K; Millar J; McCluggage WG
Am J Surg Pathol; 2011 Sep; 35(9):1331-6. PubMed ID: 21836488
[TBL] [Abstract][Full Text] [Related]
52. Cytokeratins 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma.
Berezowski K; Stastny JF; Kornstein MJ
Mod Pathol; 1996 Apr; 9(4):426-9. PubMed ID: 8729984
[TBL] [Abstract][Full Text] [Related]
53. Expression of Tn and sialyl-Tn antigens in tumor tissues of the ovary.
Inoue M; Ton SM; Ogawa H; Tanizawa O
Am J Clin Pathol; 1991 Dec; 96(6):711-6. PubMed ID: 1720922
[TBL] [Abstract][Full Text] [Related]
54. Loss of cables, a novel gene on chromosome 18q, in ovarian cancer.
Dong Q; Kirley S; Rueda B; Zhao C; Zukerberg L; Oliva E
Mod Pathol; 2003 Sep; 16(9):863-8. PubMed ID: 13679449
[TBL] [Abstract][Full Text] [Related]
55. Improved specificity of the CA 125 enzyme immunoassay for ovarian carcinomas by use of the ratio of CA 125 to carcinoembryonic antigen.
Wu JT; Miya T; Knight JA; Knight DP
Clin Chem; 1988 Sep; 34(9):1853-7. PubMed ID: 2458203
[TBL] [Abstract][Full Text] [Related]
56. Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia.
Kalir T; Wang BY; Goldfischer M; Haber RS; Reder I; Demopoulos R; Cohen CJ; Burstein DE
Cancer; 2002 Feb; 94(4):1078-82. PubMed ID: 11920478
[TBL] [Abstract][Full Text] [Related]
57. Immunocytochemical determination of EGFR, OV 632 and OC 125 in primary ovarian cancer patients.
Athanassiadou P; Athanassiades P; Kyrkou K; Lazaris D; Kyragiannis G; Petrakakou E; Michalas S
Oncology; 1995; 52(2):145-9. PubMed ID: 7854775
[TBL] [Abstract][Full Text] [Related]
58. [The role of cytokeratin 7 in the differential diagnosis of primary ovarian carcinoma and metastatic ovarian carcinoma originated from the gastrointestinal tract].
Yang W; Zhang T; Shen M
Zhonghua Bing Li Xue Za Zhi; 1998 Jun; 27(3):206-8. PubMed ID: 11244983
[TBL] [Abstract][Full Text] [Related]
59. Volume-corrected mitotic index and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors.
Miliaras D
Anal Quant Cytol Histol; 1999 Oct; 21(5):425-9. PubMed ID: 10560525
[TBL] [Abstract][Full Text] [Related]
60. The immunoperoxidase localization of tumour markers in ovarian cancer: the value of CEA, EMA, cytokeratin and DD9.
Hammond RH; Bates TD; Clarke DG; Grant AG; Haines AM; Eustace DL; Heyderman E
Br J Obstet Gynaecol; 1991 Jan; 98(1):73-83. PubMed ID: 1705435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
